Summary. Non-obese diabetic mice were treated daily with a mixture of ganliosides from day 30 until day 250 of life or until the mice became diabetic. Ganglioside treatment reduced diabetes incidence from 80-90% to 47% and from 20-30% to zero in female and male mice respectively. Gangliosides did not affect the frequency of perivasculitis. It is concluded that gangliosides can reduce diabetes incidence in non-obese diabetic mice.
The non-obese diabetic (NOD) strain of mice develops diabetes spontaneously with a markedly higher incidence in female than in male mice [1] . Perivasculitis is the first sign of lymphocytic infiltration into pancreatic tissue and starts around day 15 of life [2] . Infiltration into the islets becomes noticeable by 4 weeks of age and results in an almost complete replacement of B cells in the final stage [3] .
Much data have been accumulated in support of immunological reactions contributing to the development of diabetes. Thus, NOD mice treated weekly with the L3T4+-reactive rat monoclonal antibody GK 1.5 did not develop hyperglycaemia and mononuclear cell infiltration disappeared after 90 days of GK 1.5 administration. On withdrawal of therapy islet cell infiltration recurred, whereas blood glucose levels remained normal for more than 225 days [4] .
Furthermore, grafting of cultured BALB/c islets into diabetic NOD mice resulted in normalised blood glucose levels if the hosts were given antibody GK 1.5 [5] . In adoptive transfer experiments with spleen cells prepared from diabetic mice it was shown that L3T4 + T-lymphocytes are required to induce both insulitis and diabetes in neonatal and healthy young NOD mice [6] .
The L3T4 molecule of the mouse corresponds to the CD4 molecule on human and rat T helper cells. In humans, rats, and mice the expression of CD4 molecules can be selectively suppressed in vitro by treat-* Deceased ment with gangliosides [7] . Based on these observations we tested if gangliosides could affect diabetes incidence in the NOD mouse.
Material and methods

Mice
NOD mice were used from our colony, the spontaneous diabetes incidence being 20-30% and 80-90% in males and females respectively.
Treatment with gangliosides and cyclophosphamide
Twelve male and 30 female mice were treated with gangliosides (Cronassial, Fidia, Res. Lab., Abano Therme, Italy, contained 21% GM1, 40% GDla, 16% GDlb, 19% GTlb) from day30 until day 250 of life or until they became diabetic. The daily dosage was 50 mg/kg body weight i.p.. Twelve male and 31 female salinetreated mice served as controls. Ten 15-week old male mice received a single dose of 200 mg cyclophosphamide/kg body weight i.p. (Serva, Heidelberg, FRG). Until day 20 when the mice were killed they were given a daily dose of 100 mg Cronassial/kg body weight i.p. (10mice). Nine saline-treated male mice served as controls. Blood glucose (BG) was determined weeldy. In case of obvious polyuria additional BG determinations were performed. Hyperglycaemia (diabetes) was diagnosed when BG levels were above 11.05 mmol/1. In case of BG levels between 8.29-11.05 mmol/1 for a period of 2-3 weeks the mice were calle, d transiently hyperglycaemic.
At killing BG and plasma insulin levels as well as insulin in the pancreatic head and corpus were measured. BG was determined enzymatically, plasma insulin and acid alcohol-extracted pancreatic insulin were measured by Pharmacia-Insulin, Freiburg, FRG. Of the 
Statistical analysis
Statistical analyses were done by one-way-analysis of variance or by Chi-square test at a level of p< 0.05.
Results
Of the ganglioside-treated group 14/30 (47%) and 3/30 (10%) female mice developed diabetes and transient hyperglycaemia, respectively, whereas all male mice remained normoglycaemic. Of the saline-treated group 18/31 (58%) and 7/31 (23%) female mice became diabetic and transiently hyperglycaemic respectively. In the saline-treated group of males diabetes occurred in 5/12 (42%) and transient hyperglycaemia in 1/12 (8%) (Fig.l) .
Plasma insulin was slightly lower in diabetic than in normoglycaemic mice. Pancreas insulin, however, was significantly higher in the latter and 5-6-fold higher in transiently hyperglycaemic than in diabetic mice (Table 1) . In normoglycaemic NOD mice of the ganglioside-or saline-treated group about 70% of the islets were infiltrated by lymDhocytes. The frequency of perivasculitis was 22/mmZ~and 28/mm 2 in normoglycaemic mice of the ganglioside-and saline-treated group respectively. The ratio islet tissue/exocrine tissue was 0.5% and 0.2% in normoglycaemic ganglioside-and saline-treated mice respectively. This ratio was impressively reduced to 0.015% in hyperglycaemic mice of either group.
After pretreatment with cyclophosphamide diabetes developed in 7/10 (70%) and 7/9 (78%) of the ganglioside-and saline-treated mice respectively. Independent of the treatment pancreatic islets were corn- pletely replaced by lymphocytes in diabetic cyclophosphamide-pretreated mice. In contrast, the majority of islets were devoid of insulitis in the non-diabetic mice of either group.
Discussion
Gangliosides can impair various immunological processes such as the in vitro activation of lymphocytes by nonspecific mitogens [8] . Furthermore, inhibition of the infiltration of lymphocytes into pancreatic islets was observed after in vivo treatment of NOD mice with the anti-L3T4 antibody GK 1.5 [9] .
We found that in ganglioside-treated female NOD mice the incidence of diabetes and transient hyperglycaemia declined from 80-90% to 47% whereas in males spontaneous incidence of 20-30% was prevented. However, in saline-treated male mice spontaneous incidence had increased to 50% whereas in saline-treated females the 81% incidence reflected well the spontaneous one. Since lymphocytic infiltration into pancreatic tissue starts as early as day 15 of life [2] one may speculate that ganglioside administration before day 30 of life might have prevented perivasculitis, insulitis and the development of transient hyperglycaemia and diabetes. In agreement with Nakajima et al.
[10] treatment of NOD mice with cyclophosphamide increased the incidence of diabetes in male recipients. Pretreatment with cyclophosphamide, however, failed to affect the diabetes incidence of ganglioside-treated male mice. From the present data it is concluded that gangliosides reduce diabetes incidence in NOD mice. The frequency of perivasculitis in normoglycaemic NOD mice, however, is not modulated by gangliosides. Furthermore, gangliosides seem to affect the ratio islet tissue/exocrine tissue by favouring islet tissue.
It remains to be clarified whether the observed effects of gangliosides can be attributed to any potential action of theirs against T-lymphocytes and/or B cells.
